Fabhalta (iptacopan) - Novartis
Enjaymo (sutimlimab-jome) - Sanofi
Soliris (eculizumab) - AstraZeneca
Voydeya (danicopan) - AstraZeneca
AMY-101 - Amyndas
https://ash.confex.com/ash/2024/webprogram/Paper210885.html
 
Michael Cole, MD, DPhil1; Nikhil Ranjan, PhD1; Gloria F. Gerber, MD2; Xiang-Zuo Pan1; Daniel Flores-Guerrero3; Shruti Chaturvedi, MBBS4, C. John Sperati, MD5; Keith R. McCrae, MD6; Robert A. Brodsky, MD7
 
Nov 6, 2024
 
Prev Next